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Abstract
Background: Osteoarthritis (OA) involves changes in both bone and cartilage. These processes might be associated 
under some circumstances. This study investigated correlations between bone and cartilage degradation in patients 
with OA as a function of sex, Kellgren-Lawrence (KL) score, Body Mass Index (BMI), oral salmon calcitonin (sCT) 
treatment and diurnal variation.
Methods: This study was a 2-week, double-blind, double-dummy, randomized study including 37 postmenopausal 
women and 36 men, aged 57-75 years, with painful knee OA, and a KL-score of I - III. Subjects were allocated to one of 
three treatment arms: 0.6 mg or 0.8 mg oral sCT, or placebo given twice-daily for 14 days. Correlations between gender, 
KL score, or BMI and the bone resorption marker, serum C-terminal telopeptide of collagen type I (CTX-I), or the 
cartilage degradation marker, urine C-terminal telopeptide of collagen type II (CTX-II) were investigated.
Results: At baseline, biomarkers indicated women with OA experienced higher bone and cartilage degradation than 
men. CTX-I levels were significantly higher, and CTX-II levels only marginally higher, in women than in men (p = 0.04 
and p = 0.06, respectively). Increasing KL score was not correlated with bone resorption, but was significantly 
associated with the cartilage degradation CTX-II marker in both men and women (p = 0.007). BMI was significantly and 
negatively correlated to the bone resorption marker CTX-I, r = -0.40 (p = 0.002), but showed only a borderline positive 
correlation to CTX-II, r = 0.25 (p = 0.12). Before morning treatments on days 1 and 14, no correlation was seen between 
CTX-I and CTX-II in either the sCT or placebo group. However, oral sCT and food intake induced a clear correlation 
between these bone and cartilage degradation markers. Four hours after the first sCT dose on treatment days 1 and 14, 
a significant correlation (r = 0.71, p < 0.001) between changes in both CTX-I and CTX-II was seen. In the placebo group 
a weakly significant correlation between changes in both markers was found on day 1 (r = 0.49, p = 0.02), but not on 
day 14.
Conclusion: Bone resorption was higher in females than males, while cartilage degradation was correlated with 
increasing KL-score and only weakly associated with BMI. Bone and cartilage degradation were not correlated in 
untreated individuals, but dosing with oral sCT with or without food, and a mid-day meal, decreased bone and 
cartilage degradation and induced a correlation between both markers. Changes in bone and cartilage markers may 
aid in the identification of potential new treatment opportunities for OA.
Trial Registration: Clinical trial registration number (EUDRACT2006-005532-24 & NCT00486369)
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Background
Bone and cartilage degradation are normally tightly cou-
pled in the pathogenesis of osteoarthritis (OA), as sub-
chondral bone turnover, sclerosis of the subchondral
plate, trabecular thinning and articular cartilage loss are
coexisting macroscopic changes [1]. Experimental and
clinical observations suggest that the structural integrity
of articular cartilage is dependent on normal subchondral
bone turnover, intact chondrocyte function and ordinary
biomechanical stresses [2,3]. An increasing line of evi-
dence suggests that there are strong inter-relationships
between the subchondral bone and the articular cartilage
[1]. At present it is neither well-documented nor under-
stood which parameters are initiators or drivers of the
disease.
For the majority of patients, the etiology of OA is not
known. Some evidence indicates that OA could be related
t o  s e x  h o r m o n e s,  as  d ecr eased  e s t r og e n  l ev e ls  i n  bo t h
animal models and women are associated with increased
cartilage degradation, in addition to the well-described
increase in bone turnover [4-8]. Among the other known
r i s k  f a c t o r s  o f  O A  a r e  i n c r e a s i n g  a g e ,  s e x ,  s i g n i f i c a n t
trauma, obesity and the resulting excessive loading,
altered gait and altered biomechanics (e.g. varus or valgus
deformity) [9-17]. This long list of risk factors for the ini-
tiation and progression of OA and physiological mecha-
nisms affecting both bone and cartilage turnover are
currently under investigation by several independent
research groups using different approaches and technolo-
gies.
Biochemical markers of tissue turnover are increasingly
used in both basic and clinical research, for diagnostic,
prognostic and efficacy purposes [18,19]. In addition,
such markers may provide additional information for
understanding the pathology of disease. Osteoclast-medi-
a t e d  b o n e  r e s o r p t i o n  i n v o l v e s  t h e  c y s t e i n e  p r o t e a s e
cathepsin K, which degrades the major protein in bone,
type I collagen [20]. Cleavage of type I collagen results in
release of C-terminal telopeptide of collagen type I (CTX-
I) [20,21], which has been used extensively as a surrogate
measure of bone resorption for in vitro, preclinical and
clinical studies [20,22]. Cartilage degradation can be
assessed using the C-terminal telopeptide of type II colla-
gen (CTX-II), which is a Matrix Metalloproteinase
(MMP)-generated fragment released during cartilage
degradation in both inflammatory arthritis and OA
[23,24]. CTX-II levels can predict loss of cartilage integ-
rity, and are associated with OA and progression of OA
[12,20,25].
An optimal approach to countering progression of OA
may involve targeting the cells of both bone and cartilage.
Calcitonin, a 32-amino-acid peptide, which possesses
approved anti-resorptive abilities [26-32], has been
shown to have positive effects on both osteoclasts and
chondrocytes [33]. It has been shown to counter the pro-
gression of OA in preclinical models [34-38], and has
shown promise in preliminary clinical settings [31,39-41].
Calcitonin administration was previously limited to sub-
cutaneous or intra-nasal routes [30]. However a new oral
formulation was recently presented [30,31] which has
been proven safe and efficacious in a 3-month phase II
study including postmenopausal women [30,31,42-45],
and a dose of 0.8 mg taken bid is currently being assessed
in phase III trials in OA.
The aim of the current investigation was to use CTX-I
and CTX-II levels from OA patients taking part in a 2-
week phase I study to assess correlations between bone
and cartilage degradation in patients with OA as a func-
tion of sex, Kellgren-Lawrence (KL) score, Body Mass
Index (BMI), oral sCT treatment and diurnal variation.
Methods
Drug substance
The study drug was an oral formulation of sCT consisting
of the peptide hormone and 5-CNAC, {8-(N-2-hydroxy-
5-chloro-benzoyl)-amino-caprylic acid)} a unimolecular
enhancer of gastrointestinal peptide absorption. The
moiety was designed to deliver sCT orally without signifi-
cant enzymatic hydrolysis or alteration of the biological
characteristics of sCT. When 5-CNAC is administered
orally in combination with sCT, gastrointestinal absorp-
tion of sCT is markedly enhanced in rodents, monkeys
and humans. The sCT-5-CNAC formulation was pro-
vided by Novartis, Basel, Switzerland.
The active tablets contained either 0.6 mg or 0.8 mg of
sCT with 200 mg of 5-CNAC and were non-identical in
appearance. Two different placebo tablets were used,
each of which appeared identical to one of the sCT doses.
Neither placebo tablet contained 5-CNAC or sCT. Due to
the double-dummy design, participants took 2 tablets in
the morning and 2 tablets in the evening before dinner.
Tablets were taken with 50 ml of water.
Study design
The data are a secondary analysis of, [46], a phase-I, 2-
week, placebo-controlled, double-blind, double-dummy,
randomized, gender-stratified study including 73 sub-
jects,. Of these, 37 were postmenopausal women and the
remaining 36 were men, previously reported (osteoarthri-
tis and cartilage, in press). The study subjects fulfilled the
inclusion criteria of being generally healthy, aged 57-75
years, and the women had passed a natural or surgical
menopause at least 2 years before entering the study. At
inclusion the subjects had painful OA of at least one knee,
i.e. had knee pain for most days of the previous month,
and experienced either morning stiffness of less than 30
minutes, or had crepitus. Additionally, the painful knee
had to have a KL index score of I-III. The subjects did notKarsdal et al. BMC Musculoskeletal Disorders 2010, 11:125
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ha ve  diseases  or r ec e ive  m edica ti ons,  su c h as  bisp hos-
phonates, known to affect bone metabolism.
After consenting, the subjects were randomized to one
of 3 treatment arms: treatment with 0.6 mg of sCT (12
women and 12 men), or 0.8 mg of sCT (13 women and 13
men), or placebo (12 women and 11 men). Each treat-
ment was given twice-daily for 14 days. The morning
dose was administered between 07:00 and 08:00 at least
30 minutes before breakfast, except on days 1 and 14
when the 08.00 dose was followed by fasting for 5 hours.
The second dose was administered 30 minutes (days 2 -
13 inclusive) or 60 minutes (days 1 and 14) before evening
dinner.
The study period included an initial screening visit and
a treatment period of 14 days. Pharmacokinetic/pharma-
codynamic (PK/PD) assessments were made at baseline,
and prior to treatments on treatment days 1 and 14. Visits
were scheduled on day 1, on day 2, after 1 week of treat-
ment, on treatment day 14 for a PK/PD assessment, and
on day 15. On the first day of treatment, the subjects
arrived at the clinic after an overnight fasting period and
received the first dose of study drug at 08:00. The subjects
remained fasting until lunch was served at 13.00. A light
meal was eaten at 15:30. The second dose was given at
17:00, and dinner was served 1 hour later at 18:00. The
same dosing and meal schedule was applied on treatment
day 14.
For PD evaluation on treatment days 1 and 14 blood
samples were collected immediately prior to dosing (time
0 hrs), and at intervals of 1/2, 1, 2, 4, 6 and 8 hrs after
morning dose and, for the pre-dinner dose, immediately
prior to dosing (time 0 hrs), and at the intervals of 1/2, 1,
2, and 4 hrs post-dose. Urine samples were collected pre-
dose and at 2, 4, 6, 8, 13, and 15 hours after the morning
dose on treatment days 1 and 14. All samples were stored
at -20°C until analysis.
The study was conducted in accordance with Helsinki
Declaration II, version II. The study was approved by the
local Danish Ethical Committees, and conducted in Balle-
rup and Vejle, Denmark. The study was registered as
EUDRACT: 2006-005532-24
Biochemical assays
Serum CTX-I was determined by the Serum CrossLaps
One Step ELISA (IDS Nordic, Herlev, Denmark) [47].
Urine CTX-II was determined using the Urine Cartilaps
ELISA (IDS Nordic, Herlev, Denmark). Urinary creati-
nine was measured by a routine chemistry method and
used for calculation of creatinine-corrected urinary CTX-
II concentrations.
Statistical analysis
For correlations the 0.6 and 0.8 mg sCT groups were
combined into one sCT group. To assess changes in
serum CTX-I and urinary CTX-II after dosing, values
were calculated for each person and expressed relative to
the pre-dose value. Data of serum CTX-I, urinary CTX-
II, and relative levels of urinary CTX-II were logarithmi-
cally transformed to obtain normality and symmetry of
variances.
Analysis of variance (ANOVA) was used for compari-
son of the continuous variables of baseline characteristics
between the three treatment groups. Fisher's exact test
was applied for assessment of the proportions of subjects
classified in KL-score groups between the three treat-
ment groups. The general linear ANOVA model was
applied for assessment of differences of baseline levels of
serum CTX-I and urinary CTX-II between genders, and
for assessment of their relationship with KL-scores and
BMI. In these models the baseline value of the biochemi-
cal marker was used as a response variable and KL-score
and gender or BMI and gender were included as fixed
effects. Spearman rank correlation coefficient was used
to assess the correlation between the levels of serum
CTX-I and urinary CTX-II in placebo and the sCT-
treated subjects before and during treatment.
A difference was considered significant if the p-value
was less than 5%. All statistical calculations were per-
formed using the SAS software package (release 9.1, SAS
Institute Inc., Cary, NC, USA).
Results
The demographic characteristics are presented in Table
1. No relevant differences within the individual gender
treatment groups were present, and all three treatment
groups had similar numbers of patients with KL I, II and
III scores.
Baseline measurements of CTX-I and CTX-II showed
no significant differences between the treatment groups
(Table 2). However, women had higher serum CTX-I
baseline levels than men, indicating higher bone resorp-
tion: this difference was statistically significant (p = 0.04)
(Figure 1). While the baseline urine CTX-II levels in
women were slightly higher than in men, the difference
was of borderline significance (p = 0.06).
At baseline, correlations between CTX-I and KL-score
were not found (Figure 2A). Although a trend towards an
increase in CTX-I with increasing OA severity was seen
in women, it was completely absent in men. On the other
hand, CTX-II levels were significantly correlated to
increasing KL-score in both men and women (p = 0.007)
(Figure 2B). The effect was more pronounced in women
than in men.
Investigations of the correlation between BMI and the
two markers revealed that CTX-I was negatively corre-
lated to BMI, r = -0.40 (p = 0.002) (Figure 3A), whereas
CTX-II showed a weak and non-significant positive cor-
relation with BMI, r = 0.25 (p = 0.12) (Figure 3B). No dif-Karsdal et al. BMC Musculoskeletal Disorders 2010, 11:125
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ferences in correlations between BMI and the markers
were observed between genders.
The correlation between changes in CTX-I and CTX-II
in response to treatment was investigated on both treat-
ment days 1 and 14 of the study. Before morning dosing
on treatment day 1, no correlation was seen between the
two markers in either the placebo or the combined 0.6
and 0.8 mg sCT dose groups placebo or sCT groups. (Fig-
ure 4A &4G). These findings were similar at treatment
day 14 (Figure 4D &4J), although a trend towards a corre-
lation was seen in the sCT group (r = 0.26, p = 0.07). At
noon, i.e. 4 hours after dosing, a significant correlation (r
= 0.71, p < 0.001) between changes in CTX-I and CTX-II
was seen in the sCT group on both days 1 and 14, indicat-
ing reduced degradation of both bone and cartilage,
whereas in the placebo group a weakly significant correla-
tion was found on day 1 (r = 0.49, p = 0.02), but not on
day 14 (Figure 4B, E, H, &4K). Finally, the evening mea-
surements (4 hours after the second dosing, 3 hours after
dinner), showed a clear and significant (r = 0.54, p  <
0.0001) correlation between changes in CTX-I and CTX-
II in the sCT group on both days, again indicating sup-
pression of bone and cartilage degradation. No correla-
tion was observed in the corresponding placebo groups
regardless of the day (Figure 4C, F, I, &4L).
CTX-I displayed marked diurnal variation, in which a
more than 50% decrease in levels was seen as a response
to intake of lunch in the placebo group. CTX-II displayed
lower levels of diurnal variation in the placebo group;
however the kinetics of the changes were comparable to
those in CTX-I (Figure 5A), indicating that CTX-II levels
also are affected by the lunchtime meal. In the combined
sCT treatment group analysis, robust reductions in both
CTX-I and CTX-II were observed shortly after the morn-
ing dose, albeit with a more rapid reduction in CTX-I
than CTX-II (Figure 5B). The marker levels remained
suppressed throughout the day and early evening. The
data are modified from [46].
Discussion
Ample evidence of a concomitant breakdown of bone and
cartilage is found in the pathogenesis of OA in both clini-
cal [11,48] and preclinical settings [49-51]. This present
study elaborates on this potential relationship by demon-
strating that: 1) Women have higher bone resorption and
cartilage degradation than men, 2) The KL score is signif-
icantly associated with cartilage, but not bone, degrada-
tion markers, 3) BMI is significantly and negatively
correlated to bone resorption, but only shows a border-
line positive correlation to cartilage degradation, 4)
Untreated individuals do not display an obvious correla-
tion between bone and cartilage degradation markers,
whereas calcitonin treatment and food intake induced a
clear correlation between these markers.
The present investigation indicated that women have
higher cartilage degradation compared with men in all
three KL categories. Such OA may be referred to as a sys-
temic, metabolic form of OA [1], which is supported by
our finding that bone resorption, indicated by CTX-I lev-
els, was higher in women than in men. Similar findings
have been shown for postmenopausal women in whom
OA is more pronounced, than in the pre-menopausal
population [4,52]. Furthermore, these findings also corre-
late with the notion that prevalence of OA is higher in
women, although there are subpopulations or individual
joints where the opposite appears to be true [10,53-55].
An alternative approach to investigating the correlation
between bone and cartilage turnover and deterioration in
the pathogenesis in OA is through analysis of the
response to various treatments in both preclinical and
clinical studies. In particular reference to the notion that
cartilage degradation was higher in females compared to
that of males, we have previously demonstrated the thera-
peutic benefit of the selective estrogen-receptor modula-
tor (SERM), levormeloxifene, in a phase II trial assessing
Table 1: Baseline demographic characteristics of study 
population
Placebo 0.6 mg sCT 0.8 mg sCT p-value
Females n = 12 n = 12 n = 13 -
Males n = 11 n = 12 n = 13
Age (yrs) 65.7 (4.1) 64.5 (4.4) 66.7 (4.1) 0.43
64.6 (3.7) 65.3 (1.4) 64.0 (4.0) 0.58
YSM (yrs) 21 (8) 15 (6) 17 (6) 0.14
-- - -
Height (cm) 168.2 (5.1) 167.2 (7.7) 161.9 (5.5) 0.03
177.8 (7.1) 176.9 (6.1) 175.5 (7.9) 0.73
Weight (kg) 76.4 (15.2) 73.4 (10.3) 78.7 (13.5) 0.61
89.0 (15.2) 85.2 (9.0) 91.9 (17.0) 0.51
BMI (kg/m2) 27.0 (5.6) 26.4 (4.1) 29.9 (3.9) 0.13
28.2 (5.1) 27.2 (2.4) 29.7 (4.4) 0.32
KL Index I: 7 (30%) I: 7 (29%) I: 9 (35%) 0.80
II: 8 (35%) II: 11 (46%) II: 12 (46%)
III: 8 (35%) III: 6 (25%) III: 5 (19%)
Values given are mean (SD). Years since menopause (YSM), body mass 
index (BMI), Kellgren-Lawrence (KL). The p-value column refers to the 
significance of the comparison of the three treatment groups.Karsdal et al. BMC Musculoskeletal Disorders 2010, 11:125
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the prevention of both bone loss and cartilage degrada-
tion during a 12 month period [8]. Levels of both CTX-II
and CTX-I, as markers of cartilage and bone degradation
respectively, decreased by approximately 50% in the treat-
ment group compared with baseline, and CTX-II levels
were restored to premenopausal levels. Similarly, another
group found that cartilage degradation in 384 postmeno-
pausal women was significantly lower in women receiving
hormone replacement therapy (HRT) compared with
women not receiving HRT [4]. These data are in align-
ment with the recent analysis of the Women's Health Ini-
tiative studies, which documented that women taking
estrogen had less total joint surgery compared with
women taking placebo [56]. The findings, taken together
with the previously mentioned over-representation of OA
in women compared with men, support the hypothesis
that sex hormones are related to the incidence of OA. In
addition, experimental studies in monkeys [57,58] and
rats [59] have shown that estrogen depletion results in
increased bone turnover and accelerated cartilage break-
down. These combined findings enable a deeper under-
standing of the rationale of the elevated CTX-II level in
females compared to that of males.
In the current study a clear correlation between mark-
ers of bone and cartilage degradation was seen after treat-
ment with calcitonin, but not in untreated individuals.
This is interesting, as suggest that only in some situation
a correlation between bone and cartilage turnover is
observed. To highlight a causal relationship between
bone and cartilage turnover in the pathogenesis of
osteoarthritis, Duong and colleagues investigated the
effects of intravenous bisphosphonate treatment on bone
turnover and development of OA in a traumatic model of
OA, the anterior cruciate ligament model (ACLT)[3,50].
Bisphosphonate treatment resulted in a 50% decrease in
disease severity scores, demonstrating the importance
and coupling between bone and cartilage health. Addi-
tional support for the role of the subchondral bone in OA
was found in studies examining the effect of calcitonin in
ACLT dogs [36,38]. Calcitonin significantly affected tra-
becular structure and prevented subchondral bone
resorption and trabecular thinning, which was speculated
Figure 1 Baseline concentrations of serum CTX-I and urinary CTX-II measured in samples collected immediately prior to first dosing at 
treatment day 1 stratified according to gender. Values shown are geometric mean +1 SEM.Karsdal et al. BMC Musculoskeletal Disorders 2010, 11:125
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to be a major factor in the reduced cartilage degradation
[32,35,38]. However, the mode of action of calcitonin may
be different from other anti-resorptives, as calcitonin was
demonstrated to have both direct and indirect action on
articular cartilage [30-32,35,36,38,40,60-64], which may
complicate the interpretation of this findings. In addition,
even in the face of the diversity of animal models that
exists and have been employed in both pharmacological
research and in the understanding of the pathogenesis of
OA, cautions must be applied. Animal models may not
adequately reflect i) the diversity of the disease status ii)
initiation or iii) progression in man, which currently is
heavily debated in the field [65,66].
Bone and cartilage metabolism has been shown to be
correlated in many studies of anti-resorptive treatments
[1,31]. However, recently tibolone, a synthetic steroid
with estrogenic, androgenic, and progestogenic proper-
ties, was shown to strongly inhibit bone resorption by
6 0 %  w i t h  n o  p o s i t i v e  e f f e c t s  o n  c a r t i l a g e  d e g r a d a t i o n
[67,68]. This further highlights that bone and cartilage
turnover may be linked under some pathological and
physiological processes and conditions, but not others.
Taken together, this increasing line of evidence points
toward some anti-resorptive treatments, such as bisphos-
phonates, calcitonin, estrogen or SERMs, having positive
effects on both cartilage and bone degradation, possibly
due to a tight coupling between these compartments.
Whatever the underlying reason is for the concomitant
degradation, a dual-action OA therapy that can protect
both bone and cartilage from deteriorating further, would
seem ideal. An interesting question is whether some of
the anti-resorptives (ie, calcitonin and estrogen) may, in
addition to their direct effects on osteoclasts and bone
turnover, provide additional benefits by targeting chon-
drocytes directly.
Weight is considered an important risk factor for OA
[69,70]. In the present study we found a negative correla-
tion between BMI and the marker of bone resorption,
which could in part be due to the peripheral estrogen
production of adipose tissue [71-73]. This may explain
the only borderline positive correlation between cartilage
degradation and BMI, which was slightly surprising since
OA and obesity are correlated in many cases [69,70]. Not
surprisingly, cartilage degradation was strongly associ-
a t e d  w i t h  K L - s c o r e ,  i n  c o n t r a s t  t o  b o n e  r e s o r p t i o n
[25,74].
Diurnal variation is a well-established and important
parameter of bone turnover, with bone resorption marker
levels decreasing by approximately 50% after food intake
compared with those of fasting individuals, and an
equally large increase in bone resorption marker levels
occurring during the night [75-77]. In the present study
we found a similar decrease in bone resorption after meal
intake at 13.00 hours, approximately 60%, (CTX-I). A
lower decrease in cartilage degradation after meal intake
of approximately 30% was observed. It has previously
been suggested that hormones impacted by food intake
may positively affect bone metabolism. An example of a
hormone affected by food intake is the glucagon-like pep-
tide-2 (GLP-2), which has a positive effect on calcium
metabolism and has been shown to be a strong physiolog-
ical inhibitor of bone resorption [78]. GLP-2 was identi-
Table 2: Baseline values of serum CTX-I and urinary CTX-II
Placebo 0.6 mg sCT 0.8 mg sCT p-value
Females
sCTX-I (ng/ml) 0.758
(0.536-1.073)
0.669
(0.503-0.891)
0.555
(0.378-0.817)
0.09
uCTX-II (ng/mmol) 303
(161-570)
410
(268-626)
293
(192-449)
0.21
Males
sCTX-I (ng/ml) 0.539
(0.413-0.704)
0.588
(0.353-0.981)
0.504
(0.340-0.747)
0.64
uCTX-II (ng/mmol) 278
(200-387)
256
(159-411)
263
(153-455)
0.91
Values given are geometric mean (± 1SD range). The p-value column refers to the significance of the comparison of the three treatment 
groups.Karsdal et al. BMC Musculoskeletal Disorders 2010, 11:125
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Figure 2 Baseline concentrations of A) serum CTX-I and B) urinary CTX-II, corrected to creatinine, measured in samples collected immedi-
ately prior to first dosing at treatment day 1 and stratified according to KL-score index for each gender. Values shown are geometric mean 
+1 SEM.Karsdal et al. BMC Musculoskeletal Disorders 2010, 11:125
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Figure 3 Relationship between baseline concentrations of BMI and A) serum CTX-I and B) urinary CTX-II measured in samples collected im-
mediately prior to first dosing at treatment day 1. Females: filled circles; Males: open circles.Karsdal et al. BMC Musculoskeletal Disorders 2010, 11:125
http://www.biomedcentral.com/1471-2474/11/125
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Figure 4 Relationship between serum CTX-I and urinary CTX-II (corrected to creatinine) in untreated subjects and subjects treated with 
sCT. A) & C) Concentrations in samples collected at 08:00 immediately prior to first dosing at treatment day 1. B) & D) Concentrations measured in 
samples collected at 12:00, i.e. 4 hours post-morning dose, relative to pre-dose at 08:00. C) & I) Concentrations measured in samples collected at 21:00, 
i.e. 4 hours after the pre-dinner dose, relative to pre-dose at 17:00. D) & J) Concentrations in samples collected at 08:00 immediately prior to dosing at 
treatment day 14. E) & K) Concentrations measured in samples collected at 12:00, i.e. 4 hours post morning dose, relative to pre-dose at 08:00. F) & L) 
Concentrations measured in samples collected at 21:00, i.e. 4 hours post pre-dinner dose, relative to pre-dose at 17:00.Karsdal et al. BMC Musculoskeletal Disorders 2010, 11:125
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fied in a systematic screening, using CTX-1, of hormones
related to postprandial regulation of bone resorption
[78]. In alignment, other hormones that affect cartilage
metabolism may be identified by a systematic screening
of the response of bone resorption and cartilage degrada-
tion biochemical markers.
This novel oral form of sCT have been investigated in
other Phase I and II clinical settings, [30,31,46,79-83].
Whether this novel oral form of calcitonin may provide
clinical benefit to patients remain to be presented in piv-
otal clinical trials. These Phase III clinical trials are cur-
rently ongoing.
Conclusion
Biochemical makers in this study show that bone resorp-
tion is correlated with female gender, while cartilage deg-
radation is correlated with increasing KL-score and only
weakly correlated with BMI. Furthermore, in untreated
patients with OA, bone and cartilage degradation is not
correlated. However, a lunchtime meal in untreated
patients, and treatment with oral sCT, regardless of
whether food is taken or not, prevent degradation of both
tissues to varying degrees, and produce a correlation
between CTX-I and CTX-II. Together with findings from
other published studies, it seems that bone resorption
and cartilage degradation are influenced to differing
degrees by various physiological and pathological situa-
tions, as well as by food intake and hormone therapy. The
use of biomarkers to assess and monitor degradation of
these key tissues may aid in the early identification of
treatment opportunities for OA.
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